November 3, 2026 Type 1 diabetes briefing: trials, device safety, and research signals
A daily Type1Cure briefing built from current official and public source pulls, with each item labeled by source, evidence class, and family relevance.
The short version
The November 3, 2026 feed is strongest in three lanes: device safety, recruiting studies, and recent research records. Type1Cure treats safety and trial records as higher-priority signals because they can affect what a family may need to check, ask, or watch next.
This is not a medical recommendation. It is a source map and plain-English triage layer designed to help families decide what deserves a closer look with their care team.
Signals in the feed
- Tandem Diabetes Care, Inc.: Tandem Mobi Insulin Pump, Models: 1004004, 1010750, 1012676, 1012719, 1013655, 1013656, 1013501, 1013700, 1014081, 1014801, 1014811, 1014813, 1014936, 1016911, 1016912, 1016913, 1... — Tandem Diabetes Care, Inc. ( Tandem ) has identified that certain Tandem Mobi insulin pumps may generate false-positive occlusion alarms when no actual insulin flow obstruction is present. Investigation determined that...Source
- Medtronic MiniMed, Inc.: Generic Name: MiniMed Go App Generic Name: MiniMed Go App Model/Catalog Number: MMT-8600 (iOS), MMT-8601 (Android) Software Version: Software version 1.2.1 Product Description: Th... — A software defect in which existing users who had previously configured and enabled the long-acting dose reminder feature in version 1.2.0 or earlier experienced failure of the long-acting dose reminder after updating t...Source
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes — RECRUITING, PHASE1, PHASE2. Interventions: Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab. Locations: Los Angeles, California, United States | San Francisco, California, United States | Ne...Source
- SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes — RECRUITING, PHASE2. Interventions: High Dose SAB-142, Low Dose SAB-142, Placebo. Locations: San Francisco, California, United States | San Jose, California, United States | Aurora, Colorado, United States. This is a Pha...Source
- Think-Find-Solve Activities for Insulin Self-Management in Type 1 Diabetes — RECRUITING, NA. Interventions: Insulin Self-Management Know-Find-Solve Activity Book, Routine education. Locations: Istanbul, Turkey (Türkiye). Children with type 1 diabetes require lifelong insulin therapy. However, im...Source
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults — RECRUITING, PHASE3. Interventions: Baricitinib, Placebo. Locations: Santa Barbara, California, United States | Tallahassee, Florida, United States | Iowa City, Iowa, United States. The purpose of this study is to find o...Source
- Medtronic MiniMed, Inc.: Brand Name: MiniMed Flex Product Name: MiniMed Flex Insulin Pump Model/Catalog Numbers: MMT-8062; MMT-8072 Product Description: The MiniMed Flex pump is an alternate controller en... — Some MiniMed Flex insulin pumps were released with missing (i.e., devices with no result or abort test results are presumed to have failed) or failed verification test results in one or more of 9 functional tests. The u...Source
How to use this briefing
Start with the evidence label. Official registry and regulator records are not the same thing as advice, but they are stronger source material than a repost, rumor, or promotional headline.
For trials, check eligibility, location, burden, intervention, and contact details at the original registry. For device safety, check exact product names, models, lot numbers, software versions, and manufacturer instructions.
This article is an evidence-labeled information brief, not medical advice. Use the linked source records and your care team before making treatment decisions.